News: UCB SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

65.79EUR
19 Dec 2014
Price Change (% chg)

€0.77 (+1.18%)
Prev Close
€65.02
Open
€65.36
Day's High
€66.68
Day's Low
€65.36
Volume
346,317
Avg. Vol
316,780
52-wk High
€75.62
52-wk Low
€50.11

Search Stocks
Select another date:

Tue, Dec 16 2014

BRIEF-UCB, Advent International and Avista Capital Partners terminate acquisition of Kremers Urban

* UCB, Advent International and Avista Capital Partners mutually agree to terminate acquisition agreement for Kremers Urban

BRIEF-UCB announces partnership with Daiichi Sankyo in Japan

* Announces partnership with Daiichi Sankyo for co-commercialization of Lacosamide in Japan

BRIEF-UCB Phase 3 clinical study on VIMPAT meets primary efficacy endpoint

* Phase 3 clinical study evaluating VIMPAT (lacosamide) meets its primary efficacy endpoint

UCB revenue up 6 pct in Jan-Sept, keeps outlook

BRUSSELS, Oct 24 - Belgian pharmaceutical company UCB reported a 6 percent rise in revenue in the first nine months of 2014 as improved sales of its leading three drugs easily made up for erosion of a former blockbuster and maintained its full-year outlook.

BRIEF-UCB expects core earnings per share in the range of 1.90-2.05 euro

* First nine month revenue up 6 pct to 2.6 billion euro (up 8 pct at constant exchange rates)

Deals of the day- Mergers and acquisitions

Oct 23 - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Thursday:

RPT-Market Chatter- Corporate finance press digest - Oct 23

Oct 23 - The following corporate finance-related stories were reported by media:

Market Chatter- Corporate finance press digest - Oct 23

Oct 23 - The following corporate finance-related stories were reported by media:

Exclusive: Advent, Avista near deal for UCB's Kremers Urban - sources

- A consortium of buyout firms Advent International Corp and Avista Capital Partners is in advanced talks to acquire UCB SA's U.S. generic drugs unit Kremers Urban Pharmaceuticals Inc, according to people familiar with the matter.

BRIEF-UCB and Amgen announce results from several exploratory analyses of Phase 2 study of romosozumab

* UCB and Amgen announce results from several exploratory analyses of Phase 2 study of romosozumab

Select another date:
Search Stocks